Eli Lilly, the maker of the diabetes drug Mounjaro and weight loss drug Zepbound, on April 1 sued the Houston-based Empower Pharmacy ... as tirzepatide and semaglutide. The suit challenges ...

A Houston-based compounding pharmacy ... the Federal Food, Drug, and Cosmetic Act. The FDA delivered the warning letter at the beginning of April following an inspection of Empower’s Houston ...

If you’ve received medication through popular telemedicine companies like Hims & Hers Health, you’re probably familiar with drug compounding ... s 14). Empower Pharmacy, in Houston, is ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Notably, the enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001). Enobosarm 6mg + semaglutide dose was not better than the Enobosarm ...

Notably, the enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001). Enobosarm 6mg + semaglutide dose was not better than the Enobosarm 3mg + ...

Veru Inc.--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 ----Topline efficacy and safety data for Phase 2b extension maintenance study expected ...